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What distinguishes a remarkable Pathology 
Department from an average one? Faculty members 
and technologists who are committed to provide 
better patient care with accurate rapid delivery 
of laboratory test results, faculty members and 
technologists who have advanced subspecialty 
trainings and are dedicated to teach and mentor the 
leaders of the future. These qualities are exactly what 
sets the Department of Pathology and Laboratory 
Medicine at Aga Khan University apart from those at 
other institutions.
First issue of Labrad for the year 2020 is in your 
hands. We always encourage residents, technologists 
and faculty to come together and submit articles. 
In this issue we have some good reads contributed 
by small teams. Some such examples in the current 
issue of Labrad are: “Role of Immunoflorescence 
Studies in the Diagnosis of Autoimmune Disorders” 
written by a team of technologists and faculty 
from Histopathology, similarly “Overview of 
Common Myeloproliferative Neoplasms” by team 
from Hematology, “Therapeutic Drug Monitoring 
of Methotrexate: factors resulting in delayed 
clearance” by technologist and faculty from Clinical 
Chemistry, “E-Cigarette, Vaping Associated Lung 
Injury, Histopathological Diagnosis” from team of 
histopathology and last and the best is the partnership 
of Pathology and Radiology in the article “Radiology 
Pathology Correlation. Bone Pathology”. 
Please welcome our new associate members of 
Labrad who have joined our team from this year. My 
editorial team has several plans for improvements of 
Labrad during our tenure; we have already started 
the working. Don’t forget to take a look at two of the 
sections Labrad team introduced last year:
• The Best of the Past
• Polaroid
Happy reading ☺
Dr Lena Jafri
Clinical Chemistry 
From the Editor’s Desk
Diagnosis of connective tissue and 
rheumatological disorders can be challenging 
task for the clinicians.  The term connective 
tissue disorder encompasses a variety of distinct 
diseases which have one thing in common; 
that is the presence of circulating autoantigens 
in the patients’ blood. The detection of these 
autoantibodies in the laboratory may help the 
clinicians in confirming the diagnosis. A variety 
of laboratory based techniques are available to 
detect the relevant autoantibodies in patients’ 
sera. However according to the American 
College of Rheumatology (ACR), Indirect 
immunofluorescence Assays (IIFA) on Hep-2 
cells is the gold standard for autoimmune body 
screening in patients with systemic autoimmune 
rheumatic diseases. IIFA has a good sensitivity 
and it detects a wide range (approximately 100 
to 150) of nuclear and cytoplasmic autoantigens. 
Due to its high sensitivity, it is often employed 
as the first line diagnostic test that detects even 
those autoantigens which may be missed by other 
commercially available multiplex ANA tests. 
Some of the patterns that are detected by IIFA and 
the associated diseases are listed in Table 1.
Role of Immunofluorescence Studies in the 
Diagnosis of Autoimmune Disorders
Samar Naz, Miss Iqra Saleem and Dr. Sabeeh Siddique
Histopathology
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Traditionally Hep-2 IIFA patterns were associated 
with diseases. Now it has been realized that many 
of these associations are only valid if the antigen 
specificity has been confirmed by follow-up testing. 
Therefore The International Consensus on ANA 
Patterns (ICAP) advocates that disease associations 
should be replaced by clinical relevance.
Pattern assignment in clinical laboratories has been 
inconsistent. That is why ICAP initiated the consensus 
on nomenclature & definitions of the Hep-2 patterns. 
ICAP consensus is based on the clinical relevance of 
29 Hep-2 IIFA patterns (Figure 1). The consensus on 
clinical relevance is defined in the clinical context 
of the patient, that is, suspected disease and includes 
recommended follow-up testing (antigen specific 
immunoassay). Cytoplasmic and mitotic patterns may 
also have clinical relevance and therefore appropriate 
follow-up testing is advisable. If follow-up testing 
identifies the antigen, the clinical relevance can be 
further refined. ICAP advocates that information 
on Hep-2 IIFA patterns should be reported to the 
clinicians and should be incorporated in diagnostic 
and classification criteria instead of simply reporting 
as ‘ANA Positive/Negative’.
Recently our laboratory has acquired a complete 
automation equipment (HELIOS®) for processing 
and reporting of the ANA samples. HELIOS® is the 
first fully automated IIF processes and it includes an 
integrated optical system for automatic slide reading 
which not only discriminates between positive and 
negative samples but also detects the patterns and 
end point titers. The software provided with this 
equipment has an extensive pattern library, which 
the technologist or the pathologist can access for 
academic purposes as well as for comparing the 
results of the test samples. Some of these patterns are 
shown in Figure 2.
Table 1. ANA Patterns and the Associated Diseases
ANA pattern
Homogeneous
Speckled
Nucleolar
Centromere
Peripheral (rim)
Associated Rheumatic Disease
l Systemic lupus erythematosus
l Mixed connective tissue disease
l Drug induced lupus 
l Juvenile idiopathic arthritis
l Systemic lupus erythematosus
l SjÖgren’s syndrome
l Polymyositis/dermatomyositis
l Systemic sclerosis/scleroderma
l Diffuse systemic sclerosis/scleroderma
l Polymyositis
l Limited systemic sclerosis/scleroderma
l Systemic lupus erythematosus
l Systemic sclerosis/scleroderma
Figure 1: Taken from: ICAP International Consensus on ANA 
Patterns;https://www.anapatterns.org/trees-full.php
Figure 2: Various ANA staining patterns seen on samples performed on 
HELIOS®
In contrast to the manual performance, running the 
ANA samples on an automated machine has the 
following benefits: 
 l Provides optimum and consistent conditions for  
  processing of samples
 l Minimal human involvement minimizes   
  chances of technical errors
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	 l Provides automated pattern recognition, end-
  point titer suggestions and reduction of 
  interpretation bias
	 l Less intensive training required
	 l Less labour intensive, medical technologists can  
  be spared do other chores
	 l Since the machine can run 106 samples in 
  a single batch the turnaround time is 
  significantly reduced. 
As mentioned previously that IIFA performed on 
HEp-2 cells is a sensitive test for detecting the 
autoantigens in a patient, however several points are 
worth mentioning here:
	 l A positive ANA result in conjunction with
  clinical suspicion suggests, but does not 
  necessarily confirm the presence of an 
  autoimmune disease
	 l Positive results are not uncommon in healthy  
  individuals (particularly as they age) and those 
  with certain infectious diseases or cancer 
 l In cases with strong clinical suspicion, specific 
  antibody testing may be appropriate even if the 
  ANA IFA result is negative
	 l If the ANA IFA is positive but the tested 
  antibodies are negative, the patient may still 
  have an autoimmune disease other than those 
  typically associated with the antibodies tested
IFA ALGORITHIM ACCORDING TO THE 
INTERNATIONAL CONSENSUS
Cystathionine beta Synthase (CBS) deficiency is 
an inherited metabolic disorder, in which the body 
is unable to utilize homocysteine (tHcy), leading to 
homocystinuria caused by a genetic mutation in the 
CBS gene, which results to decrease levels or absence 
of enzyme CBS and tHcy and methionine (Met) 
accumulate in the blood which leads to damage the 
nervous system. The pathway is shown in Figure 1.
CBS deficiency has an autosomal recessive 
inheritance pattern, patients have elevated levels of 
Plasma Met, tHcy and tHcy:Met ratio along with 
decreased level of cystine and cystathionine. Clinical 
features include ectopia lentis develop by the age 
of six years, osteoporosis, abnormal blood clots, 
Cystathionine Beta-Synthase Deficiency
Saba Abdul Mateen
Clinical Chemistry
Homocystinuria, Beta-Synthase Deficiency
Defective gene: CBS
Normal Cells Mutated Cells
Cystathionine
+vitamin B6
Cysteine
+vitamin B12 +vitamin B12
S-Adenosyl-
methionine
Methionine
Homocysteine
S-Adenosyl-
methionine
Methionine
Homocysteine
Cystathionine
beta-synthase
Figure 1: Metabolic pathway of Cystathionine Beta Synthase Deficiency
Reference: Dr. David Jockers et al. CBS Mutation and Low Sulfur Diet. 
https://drjockers.com/cbs-mutation-low-sulfur-diet/
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developmental delay, nearsightedness, seizures, 
intellectual disabilities, learning disabilities and 
failure to thrive. CBS diagnosed by analyzing plasma 
amino acid and confirmed by enzyme analysis.  
There are two types of homocystinuria due to 
CBS deficiency, one type response by Vitamin B6 
and the other one does not. Treatments for CBS 
disorder include a protein-restricted diet, Vitamin 
B6, vitamin B12, folate, betaine treatment, and other 
supplements. With early diagnosis and treatment, 
individuals with CBS deficient can have normal 
growth and development. However, it is still possible 
that they could develop ectopia lentis or blood clot, 
osteoporosis. Sometimes the blood clots can be 
very serious and cause damage of organs. Regular 
monitoring can be done by performing ‘plasma 
homocysteine methionine profile’.
The initial treatment of Factor VIII inhibitors 
consists of two steps. Firstly, control of bleeding and 
secondly elimination of inhibitor.
Control of Active Bleeding
Treatment strategies to control active bleeding 
include the use of desmopressin (DDAVP), factor 
VIII concentrates, activated prothrombin complex 
concentrates (aPCCs, factor eight inhibitor bypassing 
agent [FEIBA]), recombinant human factor VIIa 
and recombinant porcine sequence factor VIII 
concentrate.
The decision is based on the severity of bleeding 
and titer of the inhibitor. For non-life threatening 
bleeding, desmopressin has been used, however, it 
is rarely recommended due to overall superiority 
of factor bypassing agents. For life threatening 
bleeding, human factor VIII products (recombinant 
factor VIII or a factor VIII concentrate) at high 
doses have also been used.
For bleeding associated with a low titer inhibitor (<5 
Bethesda units). The typical dose of human factor 
VIII is 20 IU/kg intravenously for each Bethesda 
unit of the inhibitor, plus an additional 40 IU/kg, 
with monitoring of factor VIII activity, 10 minutes 
following bolus injection. Intravenous bolus dosing 
can be repeated if the increment recovery is not 
adequate. 
For patients with high titer factor VIII inhibitors (≥5 
Bethesda units) and/or severe bleeding, the use of 
FEIBA or recombinant human factor VIIa is advised. 
Human factor VIII products generally cannot be 
given in high enough amounts to overcome the 
inhibitor.
Recommended doses for FEIBA and rFVIIa are 
similar to those employed in hemophilia patients 
with inhibitors (typical FEIBA dose 75 units/kg; 
rFVIIa median starting dose 90 mcg/kg, range 45 to 
181 mcg/kg).
The use of FEIBA and rFVIIa should depend on 
local experience and their estimated cost. 
Eliminating the Inhibitor 
Elimination of the factor VIII inhibitor requires the 
use of immunosuppressive modalities.
Most commonly employed initial 
immunosuppressive regimens are glucocorticoids 
alone, glucocorticoids plus cyclophosphamide 
and glucocorticoids plus rituximab. The highest 
percentage of complete remissions (undetectable 
inhibitor levels, factor VIII levels >70 IU/mL, and 
immunosuppression stopped) were noted with 
glucocorticoids (1mg/kg/day) plus cyclophosphamide 
(2mg/kg/day) regime, followed by glucocorticoids 
plus rituximab, respectively. The median time to 
complete remission is approximately five weeks 
for the use of glucocorticoids with or without 
cyclophosphamide while rituximab-based regimens 
Treatment of Factor VIII Inhibitor 
Dr Abdul Muqtadir
Haematology
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require a period approximately twice as long. 
Another therapy for acquired factor VIII inhibitors 
is intravenous immunuglobulin (IVIG). Since only 
few patients respond to IVIG and multiple courses 
are often required, it is recommended that IVIG 
should not be used as initial therapy.
In case of pregnancy, immunosuppression with 
prednisone may be used. Other agents are generally 
avoided unless critically needed for maternal health.
Monitoring response to treatment — Bleeding 
should be evaluated clinically and by laboratory 
parameters (hemoglobin). As inhibitor titers drop 
very slowly following successful treatment, it is 
neither necessary nor advisable to check the patient’s 
aPTT or inhibitor titer more often than every two-
four weeks once immunosuppressive therapy has 
been started.
Carpal tunnel is a term that strikes fear into everyone 
that uses a computer, and we all know how much 
computers are used in laboratories and research 
in general. Carpal tunnel syndrome is a common 
condition that causes pain, numbness, and tingling 
in the hand and arm. The condition occurs when one 
of the major nerves to the hand — the median nerve 
— is squeezed or compressed as it travels through 
the wrist. Everything from data entry to notation and 
protocol documentation to grant, article, and proposal 
writing is digital today. But repetitive motion and 
associated musculoskeletal disorders (MSD) are not 
limited to computer users. I will discuss the technical 
aspects of repetition/duration and force as it applies to 
ergonomic risk in lab and office settings. And I will 
offer solutions to get the health care worker the days 
and weeks pain-free.
Breaks and Rest Combat Repetitive Motion
The definition of repetition is doing things over and 
over again. In repetitive work, the same motions 
are performed using the same parts of the body in 
the same way, time and time again. In activities 
such as typing, mousing, or entering data by source 
documents, the affected muscles, tendons, and 
joints can be used thousands of times a day, week 
after week, year after year. The risk of injury is 
even greater when repetitious jobs involve awkward 
posture (e.g. bent or flexed wrists) or forceful 
exertions such as repetitive overreaching for the 
mouse (which can lead to shoulder and neck pain). 
Our first and foremost goal from an ergonomic 
standpoint is to strive for neutral and balanced 
actions. Additionally, reducing the number of 
repetitions experienced by each set of muscles, 
tendons, and joints throughout the workday and 
allowing time for recovery is paramount. The body 
has great capacity to repair itself. Problems arise, 
however, when the amount of damage or stress 
accumulated over the course of time overtakes the 
body’s ability to repair. This is when we experience 
pain. If the cumulative damage continues without 
allowing time to recover and heal, there is the 
potential for serious injury. 
In order to introduce healing time, short breaks in 
repetitive tasks bring significant benefit. Break up 
Ergonomics In Laboratory: What You Need To 
Know About Repetitive Motion
Dr Mohammad Zeeshan 
Clinical Microbiology
Figure 1: Presentations of carpel tunnel syndrome due to compression of 
median nerve
Numbness   Pain
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mouse use, and once you get familiar with them will 
actually speed up your work. Another remedy is to 
try one of the many “alternative” or “ergonomic” 
mice now offered. Some allow one to use both hands 
for mousing, sharing work between hands. Software 
programs allow you to automate common tasks (e.g. 
autofill) and develop scripts called macros to perform, 
reduce, or eliminate many actions. Their use can 
significantly decrease the amount of typing you need to do
Exertion Force
Force is the amount of muscular effort needed to 
perform work. Fatigue and injury track with the 
amount of force exerted. The more force required, 
the higher the risk of both. Exertion force depends on 
many factors, including: 
	 l The effort used to strike an object (e.g. key 
  depression when typing)
	 l The shape and dimensions of an object you are 
  working with 
	 l How you grip an object or tool 
	 l The precision of motion required to perform the  
  task 
	 l Duration of force applied by the muscles (e.g., 
  the amount of time spent without a muscle- 
  relaxation break) 
	 l Awkward postures (bending, twisting, over-
  reaching) 
Goal number one is to always have a neutral and 
balanced posture. 
Goal two is to reduce the number of repetitions 
or duration of exertion experienced by each set of 
muscles, tendons, and joints throughout the workday.
Number three is to reduce the force applied to perform 
the task. OSHA provides excellent help through 
their eTool on 
ergonomics.2 
Strive to 
recognize and 
reduce all the 
risk factors both 
on and off the 
job to effectively 
reduce the 
potential for 
repetitive motion 
pain and injury.
data entry with variations in activity such as filing, 
reading, using the copier, or any other task that uses 
different muscles and motions than computer use. It is 
also good to include micro-breaks of just a minute or 
two every half hour or so during long data entry periods. 
Research has shown it is often better to take many 
small breaks than one long work break during the day. 
Try using software that tracks keystrokes and mouse 
movement and alerts you when breaks are appropriate.
Break Down and Analyze Tasks
It is critical to examine and analyze the work being 
performed. Examine the job on a task-by-task basis. 
In many cases we have seen unnecessary repetitive 
work performed due to poor process design or 
evolution over time. When evaluating, ask you “can 
parts of this process be automated? Can equipment 
be linked directly for data collection? Can steps be 
eliminated or modified to improve flow or actions?” 
Investigate use of barcodes and readers to reduce data 
entry or entry readable/scanable forms or other types 
of information collection. It is always worth investing 
time to engineer a solution that will save significant 
time and effort in the long run
An Example: Mouse Use
Pain is often reported from mousing and usually 
attributed to over-use, and is often combined with 
poor mouse location. The conventional mouse 
requires a great amount of work to be directed 
through one arm, shoulder, and hand. It is a good idea 
to try to distribute this work and share it between 
both sides. One approach is the use of keyboard 
commands. Most operating systems contain keyboard 
commands or shortcuts for common tasks. Taking 
the time to explore and use these can greatly reduce 
Figure 2: Methods to prevent Carpel tunnel syndrome due to mousing
BEFORE 
AFTER
Ordinary Mouse
Vertical Mouse
arm twisted
arm Neutral
WRONG!
WRONG!
RIGHT!
RIGHT!
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Science organizations, specifically in clinical 
laboratory context, rely on creative marketing and 
outreach strategies to attract top talent, showcase 
their products and services to potential clients, and 
engage the general public in science. However, many 
organizations overlook the importance of effective 
internal communications for these marketing and 
outreach efforts. For example, one shortcoming faced 
by staff is staying updated on the latest research 
news and developments in order to have regular 
content to share with the public. Thus, organizations 
would benefit from maintaining open lines of 
communication and promoting cross talk among 
staff to ensure information is shared throughout the 
organization.
Ways to Capture Content for Marketing and 
Outreach Efforts 
One of the biggest challenges for any lab’s marketing 
and outreach efforts is how to capture current and 
relevant content to feed into external communication 
products (e.g., social media posts, newsletters, annual 
reports). In many cases, laboratories operate as 
individual units, which can make it difficult for the 
rest of the organization to know what everyone is 
up to. Therefore, it is paramount for lab director to 
make a concerted effort to keep senior managers and 
communications staff informed of the most recent lab 
developments and accomplishments. Here are some 
suggestions for how organizations can use internal 
communications to streamline this process:
l Consider setting up a project or team site that can 
serve as a portal for internal communication 
efforts and gathering content from employees. If 
an in-house application is not available, there are 
many free and low-cost options (e.g., Asana.com, 
bitrix24.com) that can be tailored to such needs. 
Be sure to include help guides and other resources 
to train staff on how to use the website, along 
with other guidelines.
l Encourage different lab’s operational units to 
submit periodic updates with relevant news 
and information. These updates can be few 
outlined categories (e.g., recent publications and 
presentations, staff awards). Introduction of new 
diagnostic test, procedure or change in method 
must be communicated with relevant one-page 
detail. 
l Maintain a shared calendar where lab staff 
can add upcoming events (e.g., conferences, 
talks, outreach events) that they will be 
attending or sponsoring. This resource will 
allow communications staff to publicize the 
organization’s presence at these events. It also 
gives managers an opportunity to touch base 
with lab personnel in advance of the event to 
see whether they need any marketing materials 
or other information to effectively promote the 
organization.
l Ask sectional staff to regularly share already 
prepared materials and files that can provide 
ideas for promotions and/or can be repurposed for 
inclusion in marketing collateral. These materials 
may include open meeting minutes, presentation 
slides, and other related files (e.g., event pictures). 
l Facilitate ways for staff to talk and share their 
science in an informal setting. Some ways to do 
so include adding a quick roundtable discussion 
at regular meetings where employees can share 
updates or news or scheduling coffee breaks with 
managers. Also consider hosting inhouse research 
presentations or symposia to provide a platform 
for employees across the organization to engage 
in scientific discussion about their latest work.
l From a business development standpoint, provide
employees with internal communication 
guidelines on how to make business referrals 
of potential clients, collaborators, and other 
interested parties (e.g., event sponsors, funding 
agencies) to the organization. These guidelines 
may include holding debriefs with staff after 
events to collect contact information, using a 
shared contact management system, and making 
Effective Internal Communication in 
Laboratories
Dr Mohammad Zeeshan 
Clinical Microbiology
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prompt and effective follow-ups with contacts.
Training Lab Employees to be Brand Ambassadors
Staff members are the outward extension of any 
laboratory who commonly interface with target 
audiences, from presenting at scientific conferences 
to sharing updates on social media about their work. 
Therefore, they can be the best brand ambassadors 
to positively represent and promote the organization. 
In order to do so, it is essential to ensure lab staff 
are delivering consistent messages, equipped with 
the tools and resources to effectively communicate, 
and trained in science communication skills. Here 
are a few ideas on how to transform staff into brand 
ambassadors for the organization:
l Conduct in-house communications training and 
provide other helpful how-to guides. These topics 
can include everything from the art of storytelling 
and an intro to social media to information on 
how to talk to the press and on media relations.
l Leverage the networks of staff members to spread 
the reach of marketing efforts. For example, 
provide regular reminders requesting that 
employees share materials (e.g., forward email 
newsletters, share social media posts) with their 
contacts. Additionally, when considering what 
social media platforms to use, look at where 
employees are most active online.
l Create a downloadable communications toolkit 
to supply employees with the tools and 
resources to promote the organization’s brand. 
Sample contents of such a toolkit may include 
presentation and poster templates, logos and 
artwork, standard text for acknowledgments, 
marketing materials (e.g., brochures and fact 
sheets), and general talking points with key 
messages about the organization. Also, provide 
a way for employees to request printed copies of 
any of the materials to take along to conferences 
and other events
Here are some final thoughts on how managers 
can work with staff toward a shared goal of being 
effective communicators within and outside the 
organization:
l Adopt a culture that promotes open lines of 
 communication and transparency within the
  organization. This effort ensures information is  
 being shared with any employee who may need it 
 to do his or her job, and it also promotes
  collaboration across the organization.
l Take the time to promote staff (e.g., lab member 
profiles, employee award announcements, 
best from the past etc) in the organization’s 
communication channels (e.g. Facebook page 
or twitter), and use any potential marketing 
content that is provided by staff whenever 
possible. This will help employees recognize their 
contributions are valued, know everyone within 
the organization is being promoted equally, and 
see how the information is being used to advertise 
their work in marketing efforts.
l Show the tangible results of marketing and 
outreach efforts to acknowledge staff efforts. 
These results can include summaries of relevant 
marketing metrics (e.g., social media statistics, 
number of publications downloaded) and 
highlights of outreach events. 
l Demonstrate to employees that managers also 
value communications and staff time spent on 
these efforts by including related tasks as part 
of regular roles and responsibilities, allocating 
adequate time and resources for this work, and 
directly tying these activities to performance 
objectives.
l As communications activities take time and 
effort, provide staff with information on what 
communications resources (e.g., writing and 
editorial support, graphics design) are available 
to them, whom they can contact for help in 
this area, and any organizational approvals 
required before communicating to external 
audiences. In line with encouraging employees 
to communicate with the public, it is suggested 
to keep any media approvals to a minimum and 
instead default to training on best practices in 
media relations.
l Finally, seek out lab employees who may have 
special interest in science communications 
and in gaining skills in this area for career 
growth opportunities. These staff members 
can help coordinate communication efforts 
among laboratories, train fellow employees 
in science communications, prepare draft 
marketing materials for external use, and serve 
as a technical liaison to any public relations and 
marketing staff.
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Digital breast tomosynthesis (DBT) is a relatively new 
breast imaging technique where multiple low-dose 
mammographic images of the breast are obtained as 
the x-ray tube moves across an arc. These images are 
then reconstructed into sections or “slices” as thin as 
1 mm in a plane parallel to the detector allowing three 
dimensional estimation of tissue distribution. 
Mammography is the only screening modality that 
has been proven to decrease breast cancer mortality. 
However, the major limitation of two dimensional 
digital mammography (DM) is the overlap of tissues 
which can obscure a true lesion leading to false 
negative examination. In addition, overlap of normal 
structures can create a spurious lesion resulting 
in a false positive result. DBT helps mitigate the 
masking effect of superimposed tissues allowing 
better visualization of true lesions and decreasing 
summation shadows resulting in improved cancer 
detection with a concomitant decrease in rate of false 
positive examinations. Furthermore, the increased 
conspicuity and better localization of lesions may 
obviate the need for additional mammographic views. 
Various studies have shown that use of DBT improves 
the accuracy of screening and diagnostic breast 
imaging. When comparing DM/DBT with DM alone, 
the combo imaging resulted in 29 percent increase 
in cancer detection rate and a 15 percent reduction in 
recall rate.  
In a diagnostic setting, DBT may be employed to 
evaluate following non calcified lesions:
 a) Architectural distortion: this is a subtle 
imaging finding, the detection of which is 
important it has a high positive predictive 
value for cancer in approximately 60 percent 
of cases. 1 This is better visualized at DBT 
than at conventional mammography.
 b) Focal asymmetry: Asymmetry refers to 
small amount of fibroglandular tissue in a 
portion of the breast quadrant, is unilateral 
and lacks a similar correlate of tissue in the 
same position in the contralateral breast. 
DBT is useful to confirm and characterize 
it as a true asymmetry, dismiss it as a 
superimposition, or reclassify it as a mass.
 c) Masses: DBT can better depict the shape 
and margins of masses by elimination of 
the tissue overlap and also help in better 
assessment of the size. Furthermore, due 
to better visualization it helps in detecting 
multifocal or multi-centric disease which 
affects surgical treatment and the choice of 
mastectomy or breast conservation surgery. 
Evaluation and characterization of calcifications 
may be challenging with DBT. Large calcifications 
often cause artifacts on multiple imaging sections 
while the micro-calcifications may be blurred or less 
conspicuous. DM spot-compression magnification 
views are therefore required for complete evaluation 
of micro-calcifications.
The average glandular radiation dose is approximately 
doubled when both DM and DBT are acquired 
although it is still below the FDA limit of 3mGy for a 
phantom image. Efforts are underway to address this 
and a software has been developed for creation of a 
synthesized 2D mammogram from the tomosynthesis 
acquisition.
Despite FDA approval in 2011, the use of DBT is 
inconsistent across various imaging centers in the 
world. As with any new technology, several issues 
must be considered when implementing DBT into 
daily practice. First there is a substantial learning 
curve for interpreting DBT. Secondly increased 
number of images increases the reading time along 
with increasing the storage require-ments of the 
picture archiving and communication system (PACS). 
Moreover, management of suspicious findings visible 
at DBT alone is challenging if DBT guided biopsy 
technique is not available.
AKU has two state of the art mammography units, 
both with capability of DBT. We do not use DBT for 
routine screening, however it is used in selected cases 
mainly as a problem solving tool.
Acquiring DBT images in addition to routine DM 
Digital Breast Tomosynthesis
Dr Kulsoom Fatima
Department of Radiology
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increases the scanning time by just few minutes.
Example Cases
Case number 1: A spiculated density was seen in the 
lower half of the left breast on digital Medio-lateral 
oblique (MLO) projection (Figure 1a, black circle). 
Corresponding DBT image (Figure 1 b), did not reveal 
any suspicious abnormality in that area. Normal 
parenchyma was seen indicating that it was not a true 
density but just summation of overlying tissues.
Case number 2: A 44-year old woman presented 
with right breast lump for one year. Digital Cranio-
caudal (CC) view of the right breast showed an 
ill-defined increased density in the right retro-areolar 
region (black circle, Figure 2 a) and skin thickening 
overlying the right breast. Corresponding DBT image 
in same projection nicely depicts the spiculated high 
density mass in the right retro areolar region (Figure 2 
b). This was proven to be invasive breast carcinoma.
Case number 3: Digital Coned MLO view of the 
right breast in a 38-year old woman did not reveal 
any focal abnormality in the lower half (Figure 3 
a). Corresponding DBT image in same projection 
shows a well circumscribed benign appearing oval 
nodule with surrounding lucent halo (black circle, 
Figure 3 b) which was an intramammary lymph 
node on concomitant ultrasound. This was not 
evident on digital image due to overlapping of breast 
parenchyma.
Methotrexate (MTX) is an immunosuppressant 
drug utilized in treating post-transplant patients; 
cancer including breast cancer, leukemia, lung 
cancer, lymphoma, osteosarcoma; autoimmune 
diseases including psoriasis, rheumatoid arthritis, 
Crohn’s disease; ectopic pregnancy and for medical 
abortion. Methotrexate decreases the cell turnover 
by competitively inhibiting dihydrofolate reductase, 
an enzyme involved in synthesis of the nucleoside 
thymidine, which is in turn required for DNA synthesis. 
Therapeutic Drug Monitoring of Methotrexate: 
factors resulting in delayed clearance
Ms. Humera Asif and Dr Hafsa Majid
Clinical Chemistry
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The MTX is cleared from the body through both 
biliary and urinary routes, dysfunction renal (dose 
adjustment needed) and abnormal liver function tests 
are relative contraindication for MTX use. Excretion 
of MTX by the kidney is a result of both glomerular 
filtration and tubular secretion. Studies shows that the 
many factors which can result in delayed clearance of 
MTX, shown below:
- Methotrexate is water soluble drug and can 
 accumulate in body fluids such as ascites or 
 effusions. Methotrexate will then slowly leak 
 out of the fluid, resulting in prolonged serum 
 concentrations of MTX. 
- Reduced renal tubular transport as a result of 
decreased urine pH, Folic acid, salicylates, 
ascorbic acid can decrease clearance of Mtx. 
- Concomitant use of certain drugs also delays 
 clearance, such as;
  o Sulfonamides, salicylates, phenytoin, 
tetracycline. These drugs displace Mtx from 
binding sites on plasma proteins
  o Aminopterin (an anti-neoplastic agent), 
   interferes in analysis
  o NSAIDs, Penicillins, Probenecid, 
Gemfibrozil, Cyclosporine, Ciprofloxacin, 
Amiodarone, Doxycycline, Simvastatin. 
These drugs  compete for P-glycoprotein 
transport, CYP450 metabolism, or renal 
excretion of methotrexate
  o Furosemide, when used within 48 hours 
of the initiation of high-dose methotrexate 
can delay methotrexate clearance
  o Proton pump inhibitors (Omeprazole, 
Esomeprazole, Pantoprazole) and 
Levetiractum are also reported to delay Mtx 
clearance.
Concentration of serum MTX is determined by 
Enzyme multiplied Immunoassay techniques. Results 
are interpreted in relation to drug dose taken and 
timings of last dose, so it is important to mention 
dose & time of MTX infusion completion and time of 
sample collection on every sample request forms and/
or Computerized physician order entry (CPOE) while 
requesting MTX levels.
Myeloproliferative neoplasms (MPNs) are a distinct 
group of blood disorders characterized by massive 
production of one or more of the blood cells. This 
over-production leads to various signs and symptoms 
and compromises the quality of life of sufferers. 
Moreover, the cells produced in massive numbers are 
dysfunctional and add to the symptomatology of the 
disease.
WHO Classification of MPNs: The 2016 WHO 
category of MPNs includes the three major 
subcategories of JAK2/CALR/MPL mutation-
related MPNs [polycythemia vera (PV), essential 
thrombocythemia (ET) and primary myelofibrosis 
(PMF)], as well as four other clinicopathologic 
entities: chronic myeloid leukemia (CML), chronic 
neutrophilic leukemia (CNL), chronic eosinophilic 
leukemia not otherwise specified (CEL-NOS) and 
MPN unclassifiable (MPN-U). 
Another broad classification also distinguishes 
between these subgroups by the presence or absence 
of BCR-ABL1 fusion gene, a concerns that is typically 
helpful in clinical management and follow-up for 
these patients.
Incidence of MPNs: Incidence of these disorders 
is at a raise in our population. They usually 
affect individuals over 50 years of age (excluding 
CML). Younger individuals and even children are 
also affected in some cases (especially in CML). 
Etiological factors suggested include exposures 
to chemicals & radiations however majority cases 
remain idiopathic.
Overview of Common Myeloproliferative 
Neoplasms
Dr Hajrah Syndeed, Dr Asif Naveed, Dr Natasha Ali 
Haematology
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Overview, Pathogenesis, Signs and Symptoms for 
Common MPNs:
	 l Chronic myeloid leukemia (CML)—CML 
is considered to be a disease of adults with 
age over 50 years particularly at risk. It is also 
the most common pediatric MPN. People with 
CML initially are asymptomatic, however 
common symptoms are weakness, pale skin, 
abdominal discomfort/heaviness caused by an 
enlarged spleen, and unexplained weight loss. 
CML occurs due to abnormal chromosomes 
(known as Philedelphia Chromosome) which 
leads to a mutation BCR/ABL1. This altered 
gene makes an abnormally functional protein 
that leads to the overproduction of white 
blood cells.
	 l Polycythemia vera (PV) is a disease in 
which extensive red blood cell are produced 
in the bone marrow due to dysregulation of 
red blood cell production. Building up of 
RBCs in the bloodstream leads to increased 
viscosity of the blood causing symptoms such 
as headache, dizziness and visual problems.  
Other life threatening events such as heart 
attack or cerebrovascular accidents can also 
occur.  
	 l Primary myelofibrosis (PMF) – is a disease 
where fibrous cells gradually replace normal 
bone marrow tissue. The dense fiber network 
impairs bone marrow function and blood 
cell production and can lead to production of 
blood cells outside the bone marrow, typically 
in the liver or spleen (extramedullary 
hematopoiesis)
	 l Essential thrombocythemia (ET)—
is characterized by an increased number of 
megakaryocytes in the bone marrow as well 
as persistent increases of platelets in the 
blood. Excessive platelets are prone to initiate 
clot formation within the blood stream. Also, 
platelets may not function normally, leading 
to bleeding. 
Laboratory diagnosis for MPNs: Diagnosis of these 
disorders are usually indicated by complete blood 
count and white blood cells differential count. Various 
CBC findings for MPNs are as under:
Complete Blood Count:
CBC parameter CML PV ET MF
Hb Ranges from low to 
normal range
High
>16.5g/dL in Males
>16 g/dL in females
Normal Ranges from Low to normal
Tear drop cells are hall mark
WBC count Markedly Raised in 
majority of cases
Raised Normal Raised
Differential 
Leukocyte count
Shows presence of 
immature myeloid 
precursors, basophils and 
blasts
Usually show few 
immature myeloid 
precursors.
Normal. No left 
shift is seen
Show immature myeloid precursors, 
varying degree of blasts
Platelet count Ranges from low to 
normal/increased
Increased Increased 
and shows 
anisocytosis.
Ranges from low to normal range
Bone Marrow Biopsy
Bone Core Trephine Biopsy
CML PV ET MF
Shows presence of hyperplastic 
leucosytosis. Blasts count 
varies according to disease 
subtype
Shows Panmyelosis 
(marked increase in all cell 
lines)
Shows marked increase in 
Megakaryocytic proliferation and 
lakes of platelets with other cell 
lines within normal range
Shows presence of 
megakaryocytic atypia, 
variable blast percentage and 
other cell lines according to 
stage of disease
CML PV ET MF
Presence of hyperplastic 
leucosytosis and 
characteristically dwarf 
megakaryocytes
Panmylosis (marked 
increase in all cell lines)
Marked increase in 
Megakaryocytic proliferation with 
specific clustering patterns.
Presence of megakaryocytic 
atypia and clustering.
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CML PV ET PMF
Reticulin and trichrome stains further enhance the presence of fibrous/collagen bands in each of the case 
associated with staging and prognostic findings in each individual.
Molecular testing: According to WHO classification of MPNs, molecular testing plays a vital role in diagnosis as 
well as risk stratification for the patients. The following shows details for each common MPN:
WHO classification strongly emphasized for BCR-
ABL1 testing to be excluded before considering 
any MPN other than CML, this emphasizes the 
importance of testing BCR-ABL testing in each 
suspected case of MPN.
BCR-ABL1 Testing: The testing can be performed 
through FISH or PCR on blood/bone marrow aspirate 
samples.
Significance of BCR-ABL1 Detection: 
 1. Diagnostic significance.
 2. Targeted therapies are aimed at inhibiting 
the abnormal proteins related to genetic 
mutations in MPNs. For example, drugs 
called tyrosine kinase inhibitors (imatinib, 
dasatinib, nilotinib) can target the abnormal 
BCR-ABL protein in chronic myeloid 
leukemia cells. 
 3. Monitoring patients through BCR-ABL1 
analysis responding to tyrosine kinase 
inhibitors helps in determination of 
disease status and continuation of targeted 
therapies.
Continuous Monitoring and Follow-up: are required 
in cases of MPNs. They have a risk of advancing to 
acute leukemia (especially MF, PV and accelerated 
phases of CML). A close clinical and laboratory 
correlation is thus required for a good quality of life 
in these patients.
CML PV ET MF
BCR-ABL1 Positive BCR-ABL1 Negative
JAK2 Positive in 90% of 
cases
BCR-ABL1 Negative
CAL-R
MPL (with majority of cases)
JAK2 (with few cases)
BCR-ABL1 Negative
Positivity for JAk2, MPL, 
CAL-R may be detected as an 
evidence of clonality. 
An 18-year-old boy was presented to an orthopedic 
OPD with complains of right knee pain and 
swelling of 3 month’s duration. An x-ray knee was 
done which showed a lytic lesion in the epiphysis 
of right distal femur with well-defined sclerotic 
margins and a few calcific areas in it. (Figure 
1A). The patient underwent curettage and bone 
grafting of the lesion. Histological examination 
showed sheets of polyhedral cells. These cells 
had abundant eosinophilic cytoplasm and nuclear 
grooves. Scattered osteoclast type giant cells were 
noted (Figure 1B). Focal chicken wire calcification 
was seen (Figure 1C). Based on radiological and 
histological findings, a diagnosis of chondroblastoma 
was made.
Radiology Pathology Correlation: Bone Pathology
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology
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Discussion
Chondroblastoma is a rare, benign, locally aggressive 
bone tumour. The tumour typically affects the 
epiphyses or apophyses of long bones like proximal 
and distal femur, proximal tibia and proximal 
humerus. The tumour commonly occurs in patients 
between 10 and 25 years of age with a slight male 
predominance. Most of the patients present with 
history of localized mild pain of variable duration. 
Radiographically, chondroblastomas are seen as well 
defined lucent lesions, with either smooth or lobulated 
margins and a thin sclerotic rim. Usually arising 
eccentrically in the epiphysis of long tubular bones 
like  femur, humerus, or tibia or apophyses such as 
the greater trochanter, greater tuberosity, calcaneus, 
or talus. Internal calcifications can be seen in 40-60 
percent of cases. They range in size from one-ten cm. 
Histologically, sheets of uniform round to polygonal 
cells with well-defined cell borders are seen. The 
cytoplasm is eosinophilic, and nuclei are round 
to ovoid which often show longitudinal grooves. 
Scattered osteoclast type multinucleated giant 
cells are seen. Fine pericellular, chicken-wire type 
calcifications are pathognomonic but not seen in 
all cases as decalcification dissolves these fine 
calcifications. Secondary aneurysmal bone cyst is 
seen in up to 1/3rd of cases. Tumour cells express 
S100 protein and SOX9. Recently, a heterozygous 
mutation replacing lysine 36 
with methionine (K36M) in the 
histone H3 variant H3.3 is seen 
in chondroblastoma. Antibody 
H3K36M is a sensitive and 
specific marker for diagnosis of 
chondroblastoma. Histologically, 
the closest differential diagnosis 
of chondroblastoma is Giant cell 
tumour of bone (GCT). Both 
tumours involve epiphysis, but 
GCT occurs in patients after 
growth plate closure while 
Chondroblastoma mostly occurs 
in patients less than 20 years. 
Osteoclast type giant cells in 
GCT contain many nuclei which 
are fewer in chondroblastoma 
and these are evenly dispersed 
in GCT and scattered placed 
in chondroblastoma. Mitotic 
figures are frequent in GCT 
while few mitoses are seen in 
chondroblastoma.  Characteristic 
chicken-wire calcification is not seen in GCT. 
Immunohistochemically, GCT is negative for H3K36 
and positive for H3.3G34W. The other differential 
diagnosis of chondroblastoma is chondromyxoid 
fibroma (CMF). CMF also occurs in the same age 
group but involves metaphysis of long bones. CMF 
has a lobular architecture and myxoid background 
which is not seen in chondroblastoma and CMF do 
not contain chicken-wire type calcification. Clear cell 
chondrosarcoma (CCC) occurs in older patients but it 
also involves epiphyses of long bones. 
Histologically, cells of CCC are larger than 
chondroblasts of chondroblastoma and these contain 
abundant clear cytoplasm. Trabeculae of bone seen in 
CCC are not a feature of chondroblastoma.
Radiographic differential diagnoses include clear cell 
chondrosarcoma, osteomyelitis with abscess, e.g. Brodie 
abscess, intraosseous ganglion and giant cell tumor. 
Chondroblastomas are successfully treated by simple 
curettage and bone grafting. Local recurrence rates 
range from 14 to 18 percent. Rarely, pulmonary 
metastases may develop from histologically benign 
chondroblastomas. These metastases are clinically 
non-progressive. There are no reliable histological 
features to predict recurrence or metastasis.
A
B
C
Figure:  A). x-ray AP view shows an eccentric lytic lesion with some chondroid matrix and ground 
glass texture. B). Histologically, sheets of polygonal cells with few osteoclastic type giant cells. C). 
Characteristic chicken-wire calcification
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E-cigarette use or “vaping” has been increasing in 
popularity over the past decade, and it is commonly 
seen as a “healthier” often marketed as a safer 
alternative to smoking traditional combustible tobacco 
cigarettes. 
While they may not contain tar or some of the 
other carcinogens, in addition to nicotine, the 
vapor aerosolized by e-cigarettes is known to 
have many other additives and flavorings like 
tetrahydrocannabinol (THC- a psychoactive mind-
altering compound of marijuana that produces 
the “high”) and other plant compounds, lipid-rich 
materials (essential oils, etc). In the recent past, lung 
disease related to vaping has risen as a public health 
issue in the United States, generating considerable 
attention in the national news media. As of January 
21, 2020, a total of 2,711 hospitalized EVALI cases or 
deaths have been reported to CDC from 50 states, the 
District of Columbia, and two U.S. territories (Puerto 
Rico and U.S. Virgin Islands). Amongst them 66 
percent were male. The patients ranged from 13–85 
years, 24 being the average age.
Although several studies have described clinical 
features including respiratory symptoms (dyspnea, 
cough, and hypoxemia), constitutional symptoms 
(fever and gastrointestinal symptoms) along 
with bilateral pulmonary infiltrates on computed 
tomography chest imaging, literature is severely 
deficient in regards to the histopathologic changes 
observed in the lungs of these patients.
To date, histologic findings reported in presumed 
cases of vaping-associated acute lung injury include 
organizing pneumonia, lipoid pneumonia, diffuse 
alveolar hemorrhage, mild nonspecific inflammation, 
diffuse alveolar damage with foamy macrophages, 
interstitial and peribronchiolar granulomatous 
pneumonitis, and respiratory bronchiolitis. 
The pathogenesis of vaping-associated acute lung 
injury remains poorly understood, but much attention 
has been given recently to the possibility that this 
may represent a form of lipoid pneumonia. One 
potential explanation is the deposition of aerosolized 
oils inhaled from e-cigarettes within the distal 
airways and alveoli of these patients, inciting a local 
inflammatory response impairing vital gas exchange.  
The presence of numerous Oil Red O–positive 
macrophages in bronchoalveolar lavage (BAL) fluid 
was the only evidence to make such a diagnosis.  
(E-F) Surgical lung biopsies from a 51-year-old 
man vaping marijuana showed a vaguely nodular, 
airway-centered acute lung injury pattern with severe 
bronchiolitis, abundant fibrin within bronchioles 
and peribronchiolar airspaces, vacuolization of 
the bronchiolar mucosa and pneumocytes, foamy 
macrophage accumulation, and airway-centered 
organization.    (Butt YM, Smith ML, Tazelaar HD, et 
E-Cigarette, Vaping Associated Lung Injury 
(EVALI), Histopathological Diagnosis 
(literature review).
Dr Sahar Sulaiman and Dr Saira Fatima
Histopathology
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al. Pathology of vaping-associated lung injury. N Engl 
J Med 2019;381:1780-1).
Macrophages in vaping-related lung injury. 
(A) Foamy macrophages within airspaces, (H&E, 
×400). (B) Few intra-alveolar macrophages without 
distinctive features (H&E, ×400). 
(Mukhopadhyay S, Mehrad M,Dammert P, et al. 
Lung Biopsy Findings in Severe Pulmonary Illness 
Associated With E-Cigarette Use (Vaping) A 
Report of Eight Cases. Am J Clin Pathol January 
2020;153:30-39.)
Finding lipid-laden macrophages on lung biopsy 
specimens or BAL samples may not be a completely 
sensitive test for vaping-associated lung injury. While 
foamy macrophages were nearly universally noted, 
Mukhopadhyay et al,  did not note conspicuous foamy 
macrophages in every case included in their study.
While, performing Oil Red O stains on BAL samples 
is favoured as a less invasive option that would not 
require tissue biopsy, it should be noted that alveolar 
foamy macrophages are a very nonspecific finding. 
Increase in number of alveolar foamy macrophages 
are classically associated with lung injury due to drug 
toxicity such as amiodarone or due to aspiration. 
Thus, the clinical effectiveness of Oil Red O is 
brought into question, at least until more robust 
sensitivity and specificity data are available.
EVALI with confirmation using the CDC 
classification and Oil Red O stain. Bronchoalveolar 
lavage sample shown. (A) Thin Prep specimen 
of BAL with large intracytoplasmic vacuoles 
(inset) and (B) Oil Red O staining in large and fine 
intracytoplasmic vacuoles. (C) Cell block sections 
demonstrated numerous alveolar macrophages, with 
many containing “soap bubble”–like vacuoles (inset). 
(D) Immunohistochemical staining performed for 
CD163 demonstrated numerous alveolar macrophages.
(Anjali Saqi A, Mukhopadhyay S, Butt Y  et al, 
E-Cigarette or Vaping Product Use–Associated Lung 
Injury: What is the Role of Cytologic Assessment? 
DOI: 10.1002/cncy.22237, wileyonlinelibrary.co)
In accordance with Anjali Saqi et al, presently 
knowledge of the effects of various vaping agents 
on the respiratory tract is in its infancy. Additional 
understanding of the agents implicated in EVALI as 
well as a correlation between BAL and lung biopsy 
samples is required.
Testosterone is the principal male sex steroid 
hormone also produced in smaller amounts by the 
ovaries in women. The majority (nearly 60 percent) 
of testosterone is bound to a specific high-affinity 
protein called sex hormone-binding globulin (SHBG), 
while the rest is bound to albumin (add percentage) 
and other proteins (percentage). A small fraction 
represents the physiologically active free form that 
mediates the biological action of the hormone at the 
target tissues in both sexes.
Clinical Significance of free Androgen Index (FAI)
Mr. Sherdil Aman and Dr. Siraj Muneer
Clinical Chemistry
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The SHBG is a plasma dimeric glycoprotein and 
produced by the liver. In the circulation, SHBG 
have higher affinity of binding to testosterone than 
to estrogens (affinity to testosterone is five times 
greater than to estrogens). An increase in SHBG 
concentration decreases the bioavailability of 
testosterone and thus decreases the free hormone 
levels without noticeable change in total hormone 
levels, and vice versa. Conditions that are associated 
with decreased SHBG are polycystic ovary syndrome 
(PCOS) in females, usually accompanied with 
excess testosterone action or hyperandrogenism 
leading to hirsutism, menstrual disturbance, or 
infertility. Conditions associated with increased 
SHBG concentration such as thyrotoxicosis, liver 
disease lead to decreased free testosterone status and 
hypogonadism.
Androgen excess is the cardinal underlying 
phenomenon in a variety of disorders particularly 
PCOS, idiopathic hirsutism, and ovarian neoplasm 
in females, adrenal neoplasms, congenital adrenal 
hyperplasia as well as insulin resistance in both 
the gender. Free or bioactive testosterone that is 
responsible for the pathogenesis of androgen excess 
status appears to be of more clinical relevance. 
However, despite all advances in technology, direct 
measurement of free testosterone concentration is 
surrounded by many technical difficulties with many 
assays not easily feasible. As alternatives, calculating 
the percentage ratio of total testosterone to SHBG 
concentration, called free androgen index (FAI) 
have increasing application as diagnostic tools for 
hyperandrogenism.   It is measured by the formula 
shown below:   
This approach has improved the validity and 
efficiency of the test as a diagnostic tool. The FAI 
is a ratio used to determine abnormal androgen 
status in humans and used as a surrogate marker for 
free testosterone level, but it is not very accurate. 
Reference range of Fai is gender specific, for male s 
33.8-106 whereas for female levels between 0.51-6.53 
are considered normal. The ratio correlates well with 
free testosterone level in female compared to male. It 
is recommended that FAI ratio should be interpreted 
in clinical context.
A 41 year old gentleman with occasional headache 
 • Pilocytic astrocytoma
 • Hemangioblastoma
 • Cystic Metastasis
 • Ependymoma
Radiology Quiz 
Shayan Sirat Maheen Anwar 
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Triple negative MPNS: The term “Triple-
Negative” is used to encompass a particular subset 
of Philadelphia negative MPNs [polycythemia vera 
(PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF)] which does not show presence 
of either of JAK2, CAL-R and MPL mutations, 
found in BCR-ABL1 negative MPNs. These cases 
comprise of 10-15 percent of all cases of PMF and 
ET especially and show a more changed course of 
disease.
Impact: Triple-negative status carries prognostic 
significance in MPNs: In PMF, triple-negative status 
is associated with poorer survival, while triple-
negative ETs have favorable prognosis.
Percentage of Triple Negative MPNs:
Laboratory diagnosis: Laboratory diagnosis for 
triple negative MPNs require a similar sequence as for 
other MPNs. Clinical correlation is very important. 
Reactive causes such as: infections, immune 
disorders, secondary causes of polycythemia and 
thrombocytosis should be ruled out.
Molecular testing: As per definition, these entities 
does not show presence of BCR-ABL1, JAK2, MPL 
or CAL-R mutations. The natural query about clonal 
changes and pathogenesis of triple negative MPNs 
arises for both pathologists and clinicians. Mutations 
in LNK, TET2, DNMT3A, IDH1/2, CBL, and ASXL1 
genes as well as atypical mutation in MPL (S204P) 
have been identified.
There are over 30 missense mutations that have been 
identified in 42 genes so far and each of them pose a 
separate risk/benefit for the patient.
Newer techniques: In order to determine the 
molecular mechanisms for this subset, whole 
genome sequencing and next generation sequencing 
are successful modalities to provide much more 
information about the target mutation(s) that may be 
driving these neoplasms
New diagnostic challenge: Considering the 
prognostic role imposed by the mutations present 
in triple negative MPNs, incorporation of next 
generation sequencing, its availability and cost issues 
should be addressed for chalking out better diagnostic 
facilities as well as therapeutic targets for these 
patients is the need of hour. 
Triple Negative Myeloproliferative Neoplasms
Dr Hajrah Syndeed, Dr Asif Naveed and Dr Natasha Ali
Haematology
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1. Considering your entire time as a women 
imaging radiologist, can you recall a time (any 
AHAA moment) when you felt most alive or 
most excited about your involvement in this 
organization?
Prof Imrana Masroor: I think, for me, the part that 
I most cherished during this time was when we first 
started the Women Imaging Fellowship programme 
and inducted our very first fellow. Since then all 
fellows, which we as mentors took on have been 
remarkable. I considered it a personal achievement 
when I would train the fellow and they would be 
able to apply their expertise elsewhere. It gave me an 
immense sense of pride. 
2. Please briefly share your initial phase of 
journey i.e. from medical graduate to consultant.
Prof Imrana Masroor: For any consultant, the answer 
for this question will be anything but brief. My 
journey like everyone else’s was possible because of 
hard work and ambition. I graduated medical college 
in 1991 and completed house job in 1992. Then, like 
every other women in the workforce, I had to take 
a scheduled break to work on my family and had 
two children. I restarted work and soldiered through 
The Aga Khan University Radiology Residency 
Programme and graduated in October 1999. I was 
then taken on as an instructor in January 2000. I 
eventually became a consultant the following year in 
January 2001.
3. Let’s consider for a moment the things you 
value deeply.  Specifically, the things you value 
about yourself and the nature of your work. What 
is the single most important thing your work has 
contributed to your life? 
Prof Imrana Masroor: The attributes I value deeply, 
which in my opinion are becoming obsolete in this 
day and age, are punctuality; empathy towards not 
only my patients but my colleagues; and respect 
towards all medical staff from the housekeeping staff 
to the head of the department. I also value tolerance 
towards other’s opinions and perspective. What I 
have learned from this line of work is that even at 
this phase of my career, there is always something 
to learn. My work has instilled in me confidence and 
a sense of purpose that I otherwise would not have. 
I now have a heightened awareness of the frailty of 
human life through the experiences of my patients and 
am extremely grateful for it. 
4. As a senior most women imaging radiologist 
of the country, please share your experience 
of development of women imaging practices in 
Pakistan and its future in the next 10 years.
Prof Imrana Masroor: I think we have come a long 
way since when I first started clinical practice. Having 
said that, so much more needs to be done. There may 
be the availability of breast imaging in the form of 
ultrasounds in most urban hospitals and local clinics 
within the city. However, the problem is so much 
more than that, in terms of public awareness regarding 
breast cancer I truly believe we need a screening 
programme on a national level for Breast Cancer. 
I really hope that this gets achieved in the next 10 
years, to be optimistic. Another dilemma that I’d like 
to point out is the fact that women tend to undermine 
themselves when it comes to any symptom especially 
related to the breast or female genital tract. I really 
The Best of the Past
Radiologist #Womenimaging #Followtheirlead  
Interview recorded by 
Dr Shayan Anwar
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hope that in the next 10 years women will be aware 
enough to speak up about their concerns and not hide 
them. More so, I would like the men in our society to 
adopt the mindset of not undermining women’s health 
related problems. I really hope attitudes towards this 
change within the next decade. 
5. Any advice for Junior Radiologists?
Prof Imrana Masroor: To all those aspiring to 
become radiologist, I think the best insight I can 
relay to you is that if you’re truly passionate about 
radiology, then you will get there in the end. Practice 
and clinical exposure will make you seasoned. 
However, the right sources of information will add 
to your accolade of knowledge, so be wary of that 
too. Another thing that most people will not realize 
is how important your role is in the care pathway of 
a patient, and trust me there will be instances where 
your work, however devoid of patient interaction, 
will be undermined by other specialists and doctors 
belonging to other fields of medicine and surgery. 
This is something that can happen in this country. 
Please do not let that get in the way of how important 
your contribution can be. A special mention to all 
those aspiring female radiologist, you will probably 
have to work harder than anyone else within this field, 
keep at it. If I made it, you will too!
Parasitic infections of the gastrointestinal (GI) tract 
is a significant cause of morbidity and mortality. 
Although they are particularly more common in 
underdeveloped regions with poor sanitary conditions, 
they are also prevalent throughout the whole world.  
Clinical presentation may vary depending on the 
parasite type and the affected parts of the GI tract. 
Parasites can survive in the GI tract for years without 
causing any symptoms. They may present important 
diagnostic challenges as they can mimic important 
GI pathologies such as eosinophilic gastroenteritis, 
gluten sensitive enteropathy or inflammatory bowel 
diseases.
The common microscopic findings include:  Chronic 
and acute inflammation, increase of eosinophils, 
congestion, mucosal ulceration, necrosis, perforation, 
lymphoid aggregates, cryptic architectural distortion, 
granuloma formation, calcification, hyalinization, and 
presence of giant cells 
 According to location the common organisms include:
UPPER GIT: Giardia, hook worm or fish tapeworm, 
strongyloides stercolaris larva, ancylostoma 
duodenale and diphyllobothrium latum.
LOWER GIT: Enterobius vermicularis, 
schistosomiasis, amoebiasis, ascaris lumbricoides, 
taenia.
E.vermicularis (Oxyuris)
E. vermicularis, commonly referred to as the pinworm 
or seatworm, is a nematode, or roundworm.
Humans are the only known host, and about 209 
million persons worldwide are infected. More than 
30 percent of children worldwide are infected. Eggs 
and part of the adult worm is more likely to cause the 
inflammation of appendix
Microscopy: Cross section has narrow lateral 
cuticular alae.
Entamoeba Histolytica
It is commonly found in the inflammatory exudate 
on the base of ulcers or loose on the surface of the 
mucosa. 
Microscopy: Organisms are round to oval, have 
faintly granular cytoplasm and may be mistaken for 
histiocytes, but can readily be recognized by the very 
small pale nucleus and phagocytosed erythrocytes.
They stain positive for special stains: PAS, & 
Immunoperoxidase stain.
Histological Evaluation of Common Gastro 
Intestinal Tract Pathogens
Dr Tammana Asghar and Dr Sidra Arshad 
Histopathology 
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Giardia Lamblia
Causes malabsorption with chronic diarrhea and may 
be associated with nodular lymphoid hyperplasia.
Microscopy: Intact mucosa with blunting of villi and 
increased number of inflammatory infiltrate.
Trophozoites have a tear drop shape with paired nuclei 
(‘owl-eye’ appearance) and a central longitudinal 
axostyle.
Cytomegalovirus (CMV)
It is a double stranded DNA virus belonging to the 
herpesvirus group. 
Infection is usually seen in immunocompromised 
and debilitated patients, usually due to reactivation of 
latent infection. Tissue invasive CMV results from the 
hematogenous spread of CMV.  Gastrointestinal CMV 
disease is the most common manifestation of tissue 
invasive CMV. Most common sites of involvement are 
esophagus and colon.
Gold standard for diagnosis is histological diagnosis 
with immunohistochemistry.
Gastrointestinal bleeding is the most common initial 
presentation of CMV colitis .
Microscopy: CMV infected cells are cytomegalic 
cells, typically two to fourfold larger than normal, 
containing basophilic intranuclear inclusion bodies 
(Cowdry bodies) surrounded by a clear halo, giving 
the appearance of an owl’s eye. Many of these 
infected cells can be seen surrounding blood vessels, 
as the most commonly infected cells are endothelial 
cells and mesenchymal cells.
Herpes Simplex Virus (HSV)
Patients present with painful discrete ulcers, vesicles 
or pustular lesions in distal rectum or perianal skin.
Symptoms are similar to colitis of other causes and 
include watery or bloody diarrhea, fever, abdominal 
pain, nausea, fatigue, and weight loss.
Microscopy: Multinucleated giant cells with ground 
glass nuclei due to intranuclear virus along with 
margination and moulding.
Spirochetes
Intestinal spirochetosis is more common in the 
developing world and HIV+ patients.
Generally there are no or minimal endoscopic 
abnormalities. The infection is noninvasive, but 
uncommonly invasion occurs; it is also found 
incidentally in association with adenomatous 
and hyperplastic polyps, diverticular disease and 
inflammatory bowel disease.
Microscopy: A basophilic, fringe-like, end on end 
attachment of filamentous densely packed spirochetes 
on the surface epithelium of the large intestine 
or appendix are seen highlighted by special stain 
Warthin-Starry.
H.Pylori
Chronic infection occurs in approximately two/
three of population worldwide, prevalence is 
decreasing due to improved sanitation and 
antibiotic use. Without treatment, infection usually 
stays lifelong.
Infection conveys 15 – 20 percent lifetime risk of 
peptic ulcer disease. Atrophy with concomitant 
intestinal metaplasia and dysplasia are seedbed for 
carcinoma. Presence of active inflammation after 
eradication therapy is sign of treatment failure.
Microscopy: Bacteria is curved, spirochete-like, 
in superficial mucus layer and along microvilli 
of epithelial cells. Usually not seen in areas of 
intestinal metaplasia. They are highlighted by 
special stain Geimsa and Warthin-starry.
HSV H.PYLORI (GEIMSA STAIN)
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CMV  GIARDIA (ARROW)
H.PYLORI (H&E)                                             ENTEROBIUS VERMICULARIS
SPIROCHETES                                                                               AMOEBA
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Hemangioblastoma is considered to be benign 
neoplasm and represents 1-2% of all primary central 
tumors. Historically linked to von Hippel-Lindau 
(VHL) disease. Seventy percent do not have a family 
history. Peak age - between 20 and 50 years. MRI 
with gadolinium enhancement is the best study for 
screening. A cyst with a small mural nodule is the 
most common presentation. Cystic fluid surrounding 
the nodule is hypo intense on T1-weighted images and 
hyperintense on T2-weighted images and shows no 
post contrast enhancement (A). The mural nodule is 
isointense on T1-weighted images, demonstrates high 
signal on T2-weighted images (C ), shows diffusion 
restriction (B) and avid post contrast enhancement (A) 
Quiz Answer 
Hemangioblastoma
Retinoblastoma: Updated CAP Guidelines for 
Staging 
Dr Qurratulain Chundriger and Dr. Shabina Rahim
Histopathology 
Retinoblastoma is a malignant pediatric tumor arising 
from the retina of the eye. It is one of the tumors 
having small round blue cell morphology and is the 
most common intraocular cancer arising in children. 
The incidence globally is estimated to be roughly 
3% of all cancers occurring in children less than 
15 years of age with India and China having the 
most cases per year. It is either heritable or non-
heritable; the heritable disease being more likely 
to be bilateral and arising in children less than one 
year of age; while, the non-heritable disease being 
more likely to be unilateral. There is increased risk 
of another primitive midline neuroblastic tumor (a 
trilateral Retinoblastoma) in patients with heritable 
disease, as well as risk for developing second primary 
tumors associated with RB1 gene mutations, i.e., 
Osteosarcoma and Cutaneous Melanoma. 
The primary genetic abnormality in retinoblastoma is 
bi-allelic inactivation of the RB1 gene. This mutation 
can be either inherited from an affected parent or 
occur de novo during formation of germ cells (before 
conception) or during early embryogenesis. Other 
minor mutations include alteration in BCOR genes, 
amplification of MYCN or OTX2.
Multiple treatment options are available for 
retinoblastoma, including enucleation, local treatment 
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options like cryotherapy, thermotherapy, systemic, 
intra-arterial, intra-vitreal or sub-conjuctival 
chemotherapy and radiation to name a few. Cases 
where tumor is filling the vitreous, extending into the 
anterior chamber or causing neovascular glaucoma 
are generally treated with up front enucleation. 
This is also attempted when there is recurrence of 
progression on eye-salvage therapy. After enucleation, 
certain features are important for predicting 
disease prognosis and these need to be specifically 
mentioned in the surgical pathology report. The 
College of American Pathologists has outlined a 
synoptic reporting format addressing all the relevant 
information, based on the guidelines described in the 
Eighth edition of the American Joint Commission 
for Cancers (AJCC) staging manual. 
Unique to the eighth edition TNM classification of 
Retinoblastoma, is the inclusion of germ-line cancer 
predisposition, which is denoted by an “H category 
(Heritable trait)” to indicate the germ-line status of 
the RB1 gene (Hl). The Heritable trait is reported as 
follows: 
HX Unknown or insufficient evidence of a 
constitutional RB1 gene mutation. 
H0 Normal RB1 alleles in blood tested with 
demonstrated high-sensitivity assays. 
H1 Bilateral retinoblastoma, any retinoblastoma with 
an intracranial primitive neuroectodermal tumor 
(i.e., trilateral retinoblastoma), patient with family 
history of retinoblastoma, or molecular definition of a 
constitutional RB1 gene mutation.
For staging after enucleation, entire eye should be 
submitted for examination, as mentioned in the 
eighth edition of the AJCC staging manual. Fresh 
tissue needs to be obtained for molecular and genetic 
studies prior to formalin fixation. The following 
gross and microscopic characteristics of the tumor 
are included in the most recent version of the CAP 
cancer protocols, most of which are mandatory to be 
included in the report (updated latest on June 2017, 
available at: https://documents.cap.org/protocols/cp-
retinoblastoma-17protocol-4000.pdf).
- Procedure
- Specimen laterality
- Tumor site – before (transillumination of the  
 globe) and after sectioning the eye ball, including  
 the exact quadrant of the eye, if originating in the  
 posterior chamber
- Tumor size
- Involvement of other ocular structures –   
 Particularly the sclera and the anterior chamber.
- Growth pattern – endophytic tumors grow 
within the vitreous cavity, exophytic tumors 
grow in the subretinal space towards the choroid 
and diffuse tumors grow laterally into the retina 
without significant retinal thickening. 
- Extent of optic nerve invasion – This feature is 
of particular importance with regards to the 
status of tumor invasion in relation to the 
lamina cribrosa of the optic nerve. A tumor with 
retrolaminar invasion of the optic nerve head 
(beyond lamina cribrosa) will be classified as 
pT3b; while, if there is involvement of the cut 
head of the optic nerve (positive optic nerve 
resection margin) the tumor will qualify for a pT4 
category.
- Histologic grade – Retinoblastoma cells may 
form Flexner-Wintersteiner or Homer-Wright 
rosettes and fleurettes or areas of neuronal 
differentiation, reflecting differentiation towards 
normal retinocytes. The extent of presence of 
these specialized structures defines tumor grade, 
whereby most poorly differentiated tumors lack 
these rossettes and fleurettes and grow in diffuse 
sheets with or without anaplasia.
- Anaplasia grade – Degree of anaplasia graded as 
mild, moderate or severe, based on the highest 
level of anaplasia within the tumor. This requires 
at least 30 percent of the tumor being able to 
be graded and is an optional requirement of the 
synoptic report. 
- Cytological features suggesting MYCN 
amplification – Those being a unilateral 
Retinoblastoma with a loose cellular pattern, 
round nuclei and prominent multiple nucleoli. 
- Margins – including the resection margin of the 
 optic nerve and other soft tissue margins if 
 applicable.
- Number of lymph nodes involved by the tumor 
 (if present in the specimen)
- Pathologic TNM staging – Detailed TNM 
classification is available in the CAP cancer 
protocol document (URL provided above).
Other features of clinical and prognostic significance 
for survival include: invasion of sclera; invasion 
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of choroid (true choroidal invasion being either 
minimal or massive, see below); basophilic staining 
of tumor vessels; seeding of vitreous and involvement 
of anterior segment. Moreover, the number of 
mitotic figures in 40 fields determined by using a 
40x objective with a field area of 0.152 mm2 along 
with presence of necrosis, apoptosis, inflammation, 
calcifications, hemorrhage, retinal detachment and 
neovascularization may also be important clinically. 
True choroidal invasion is defined as one or more 
solid nests of tumor cells that fills or replaces the 
choroid and has pushing borders. Invasion of the 
sub-retinal pigment epithelium (RPE) space, where 
tumor cells are present under the RPE (but not beyond 
Bruch’s membrane into the choroid) is not choroidal 
invasion.
Minimal/Focal choroidal invasion is defined as a 
solid nest of tumor that measures less than 3 mm in 
maximum diameter (width or thickness). 
Massive choroidal invasion is defined as a solid tumor 
nest 3 mm or more in maximum diameter (width or 
thickness) in contact with the underlying sclera. 
Residual Tumor (R) Tumor remaining in a patient 
after therapy with curative intent (e.g., surgical 
resection for cure) is categorized by a system known 
as R classification as described below: 
RX Presence of residual tumor cannot be assessed. 
R0 No residual tumor 
R1 Microscopic residual tumor 
R2 Macroscopic residual tumor 
The R classification may be a useful indicator of the 
completeness of a surgical excision. Tumor involving 
the resection margin on pathologic examination 
may be assumed to correspond to residual tumor in 
the patient and may be classified as macroscopic or 
microscopic according to the findings at the specimen 
margin(s). 
All of these features serve as prognostic and clinical 
indicators of overall survival of Retinoblastoma 
patients and also serve to guide treatment. With newer 
treatment options becoming available and the option 
to be enrolled in ongoing clinical trials, there may 
be more scientific data available in the future which 
may alter the classification and staging systems. 
Remaining updated with the newest is the key to 
ensure the best practices for patients’ benefit. 
Figure 1. Gross appearance of Retinoblastoma (Picture taken from 
Ocular Pathology 6th Edition – M. Yanoff et al.
Figure 2. H&E 4x. Retrolaminar invasion of optic nerve by tumor.
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Section Of Histopathology: Newer Horizons
Dr. Qurratulain Chundriger and Dr. Arsalan Ahmed
Histopathology
The Histopathology section in the clinical laboratories 
of the Aga Khan University Hospital (AKUH) is one 
of the largest histopathology centers in Pakistan and 
the only lab in the country accredited by the College 
of American Pathologists (CAP). Currently, we are 
reporting close to 90,000 histopathology specimens, 
20,000 cytology and over 1500 flow cytometry 
specimens per year – along with ANA testing and 
semen analysis. We also get a large number of cases 
including blocks and slides for second opinion from 
labs all across Pakistan and also from Afghanistan. 
Unlike most centers, immunohistochemical studies at 
AKUH are not charged separately from the patient. 
With approximately 25 faculty members, 15 residents, 
five medical officers and more than 150 technical 
staff, we are the largest section of the department of 
Pathology and Laboratory Medicine. 
The histopathology lab has been recently remodeled, 
under our section head Dr. Arsalan Ahmed and 
inaugurated by the President Mr. Feroz Rasul. It 
comprises of a dedicated area for receiving samples 
(Figure 1), areas for grossing specimens (Figure 2), 
processing, cutting, staining and distribution benches 
(Figure 3). Previously we used to have three separate 
gross rooms, each having a grossing station along 
with cupboards and cabinets for storing specimens 
and bench supplies. This caused congestion and a 
claustrophobic environment for anyone working 
inside and therefore resulted in observation by 
CAP during the initial inspection. Therefore, the 
idea of constructing a spacious grossing hall along 
with remodeling of the rest of the histopathology 
lab occurred to fulfill CAPs’ phase II requirement, 
cope with an increasing volume and implementation 
of a “Lean method” in our section. As a result, 
these rooms have now been combined and turned 
into a large grossing hall, which has a capacity to 
accommodate upto six grossing stations. Looking 
at the statistical increase in the number of specimen 
reported annually from 2000 to 2019, this was 
the need of the hour (Figure 5). Being the largest 
histopathology laboratory in the country, it should 
be able to handle up to 200,000 specimens per year. 
This grossing hall has also merged with the cytology 
screening and flowcytometry areas previously located 
immediately behind the grossing rooms. This hall 
is a negative pressure area, maintained by exhausts 
connected with the grossing stations. The cryostats 
and staining of frozen section can now also be done 
within the grossing hall, which was previously 
done in two steps at two different benches. This 
has significantly helped to decrease the turnaround 
time for reporting frozen sections. The predictive 
“mammoth” increase in volumes may also lay a 
foundation for a physician assistant “PA” program, 
which will be the first ever in Pakistan.
The highlight of this hall is the automatic sliding 
door system. This was so important because there 
is a constant traffic of people in and out of the 
hall; technologists bringing the specimen inside 
for grossing, going back and forth with baskets of 
specimen and blocks for processing, faculty and 
residents coming and going. Now the residents or 
technologists don’t have to take off their gloves every 
time they need to go out or come in. Believe it or not, 
this used to feel like “climbing the Mount Everest” 
when one had to rush out to respond to a beeping 
pager. 
The cytology screening area has now shifted to a 
separate room, in accordance to the requirements of 
CAP. Flowcytometry reporting bench has also shifted 
to one of the larger areas of the lab. Since cytogenetics 
was shifted to Supariwala building in the molecular 
section, the dark room has now been converted in to 
semen DR reporting bench with immunofluorescence 
and our new gadget – the “Helios HELMED 
integrated optical system” which is an automated 
immunofluorescence machine – in close proximity 
(Figure 4). Liquid based cytology is another highlight 
and our Surepath equipment being under validation 
to be soon fully operational. Another newer member 
of the team is the bone processing equipment, 
including the bone cutter and Decal mate (automated 
bone decalcification) which is going to dramatically 
reduce the reporting time of bone specimen from 
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The histopathology section is the powerhouse of 
clinical and academic activities. Our team of faculty 
is in the process of expanding, which is essential to 
cope with increasing work load. With proper logistics 
and the largest faculty in the country under one roof, 
we will be a regional power. Our ambition and goal is 
to explore newer frontiers like the Gulf countries.
Our goal was to increase 
the functionality and 
maximize workflow 
efficiency within the 
same available space. 
The section is thankful 
to the entire team behind 
this process, especially 
Dr. Arsalan Ahmed in 
successfully achieving 
this goal in record time. 
We aim to continue 
providing the best of 
diagnostic and predictive 
services which are the 
backbone of any patient 
care system.
three-four weeks to three-four days. In addition, the 
renovated chair office region also houses three of 
our faculty members in their new offices, the area 
being jokingly termed as the “glass castles” among 
ourselves. 
Figure 1: The receiving bench                                           Figure 2 The new grossing hall
Figure 3: Embedding, cutting and distribution areas Figure 4: Helios HELMED integrated optical system
Figure 5. Line graph indicating the increase in the number of specimen received from the year 2000 to the year 2019.
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Aspects of Qaulity Assurance in Laboratory 
Medicine: A Road to Quality?
Sujjawal Ahmad
Molecular Pathology 
The top objective of any clinical laboratory is to give 
way to correct diagnosis and effective treatment of 
the patients. It is therefore imperative that diagnostic 
results produced are reliable. Quality laboratory 
services serve as bedrock for the decision-making 
capacity of the clinicians, healthcare workers and 
public health authorities to take appropriate curative 
as well as preventive measures for control of the 
disease. Principles of Quality management, assurance, 
and control have become the foundation by which 
clinical laboratories are managed and operated giving 
reasonable assurance that quality laboratory services 
are being provided to the patients. This implies to a 
wide-ranging concept of proper management skill and 
good laboratory practice that covers all activities both 
inside and outside laboratory.
The total testing chain in clinical laboratory involves 
several professionals and organizations in healthcare 
from the clinical decision to order a test through the 
pre-analytical, analytical and post-analytical phases 
to the value of the test result in the on-going clinical 
decisions and healthcare process. 
Image from: Theodorsson, Elvar, Quality Assurance 
in Clinical Chemistry: A Touch of Statistics and a Lot 
of Common Sense, J Med Biochem 35: 103 –112, 2016 
Defining the quality objectives is first step in 
designing and implementing a quality plan. WHO 
summarizes quality requirements as:
• right result, at the
• right time, on the
• right specimen, from the
• right patient, with result/interpretation based on 
correct reference date, and at the
• right place. (1)
Error at any of the stage - be it pre-analytical, 
analytical or post analytical - invalidates the quality 
of analysis causing laboratory to fall short of its 
quality goals.  
Procedural errors are related to unclear and 
ineffective management and planning, inadequately 
trained staff, lack of adequate Quality assurance 
(QA) and other problems that pertain to how the 
work gets done. Systematic or technical errors, on 
the other hand, are directly related to the methods 
and technologies employed in a testing procedure. 
Avoiding or minimizing procedural errors will reduce 
likelihood of technical errors.
Quality assurance is the practice that encompasses all 
activities, procedures and endeavors that a laboratory 
takes to ensure that desired quality goals are being 
achieved and maintained.  ISO, therefore, defines it as 
a part of quality management, providing confidence 
that quality requirements will be fulfilled. ISO 
9000:2005, Clause 3.2.11. The primary objectives 
of QA, thus, include identification and as well as 
qualification of errors which may cause improper 
patient results compromising quality objectives. 
These may be random, systematic or procedural 
errors, occurring in pre- analytical, analytical or post 
analytical phases of diagnostic procedures employed 
for a specific test.  QA is aimed at ensuring quality 
test results.
Quality control (QC) on the other hand covers the 
part of quality assurance which primarily concerns 
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the control of errors in the performance of tests 
and verification of test results, ensuring detection, 
reduction and correction of deficiencies in producing 
patient results. Quality control must be practical, 
achievable and affordable. Quality control can be 
implemented in two ways: Internal QC-performed 
by individual labs at their own levels. It forms the 
day to day basis working quality assurance, involving 
daily QC chart preparation.  External or inter 
laboratory QC-performed by many labs at the same 
time, monitored by one. Bias (or Analytical error) 
is estimated by participation in proficiency testing 
schemes, using certified reference materials  of 
surveys provided by various accrediting international 
organizations, including CAP, RIQAS, EQAS and 
many others. Comparisons are commonly made 
on the basis of Standard Deviation Index (SDI) or 
Z-score in some cases.
The laboratory must establish and follow written 
quality control procedures for monitoring and 
evaluating the quality of the analytical (examination) 
testing process of each method to assure accuracy 
and reliability of patient test results and reports.” 
It is therefore imperative that written procedures 
describing the validation process for new instruments 
and methods, as well as the data collected should 
be documented before a method is implemented for 
patient testing.   
A Webinar Series ‘Rare Links’
Dr. Hafsa Majid
Clinical Chemistry
A Webinar based educational series ‘Rare Links’ 
was initiated by Section of Chemical Pathology, 
from the platform of Pakistan Inherited Metabolic 
Disease Network (Pak-IMD-Net), a working group 
of Pakistan society of Chemical Pathology. Aim of 
Rare links webinar series is to provide a platform 
where national and international experts can discuss 
the inherited metabolic disease (IMD) in focus and 
share their experience of managing its patients. First 
Webinar of this series was conducted via Zoom video 
conferencing on ‘Diagnosing Urea Cycle Disorders 
(UCD)’ on 10th December 2019. 
The focus of workshop was on understanding 
Hyperammonemia, natural history, pathophysiology 
and management of UCD. Webinar started with 
introduction of all participants followed by a 
welcome address by chair Pak-IMD-Net, Dr Lena 
Jafri. She briefed the participants about the aims and 
objectives of this working group. This was followed 
by introduction to “rare links’ webinar series by 
Dr. Hafsa Majid. She highlighted the importance 
of knowledge sharing in the area of IMDs and how 
this webinar series can help bringing together health 
care persons working at different centers and are 
involved in managing patients with rare diseases. 
This was followed by lecture about approach to the 
diagnosis and management of hyperammonemia 
by Dr Aamir Ijaz, co-chair, Pak-IMD-Net. Next 
was a talk given by Dr Lena Jafri to further our 
understanding of the natural history, pathophysiology 
and management of UCD. Drs Sibtain Ahmed and 
Hafsa Majid presented case studies of UCD. An 
International expert on IMDs Dr Samir Munir, 
Metabolic Physician, working at Great Ormond Street 
Hospital for Children, London, United Kingdom gave 
a talk about management of patients with UCDs. In 
the end Dr Aysha Habib presented the data of IMDs 
patients presenting at a clinical laboratory, Aga Khan 
University.
It was a very successful event, with more than 80 
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Figure: Participants from London, United Kingdom and different Cities of Pakistan attended the Rare Links Webinar via Zoom Video Conferencing
participants from 14 different institutes and 7 cities of 
Pakistan. This was first webinar of this series, we plan 
to conduct more such activities under the banner of 
‘Rare Links’
A Look into the Eye can Unleash Vital 
Diagnostic Pearls for Rare Disorders
Dr Sibtain Ahmed 
Clinical Chemistry
Ophthalmologic manifestations are common in 
various inherited metabolic disorders (IMDs). 
Literature review revealed that the eye is the fourth 
most common organ system affected by IMDs. The 
age of onset of ocular abnormalities is however 
variable, ranging from childhood to infancy or 
early juvenile years. The following table enlists 
the common ocular manifestations that can serve 
as important diagnostic clues for certain IMDs. 
The following table enlists various IMDs and the 
associated ophthalmologic findings.
Disorder Ophthalmologic manifestations
Fabry’s disease opacities in the corneal epithelium, engorged conjunctival vessels and congested retinal vessels
Cystinosis opacities in the stroma, deposition of distinctive iridescent crystals in the cornea
Wilson’s disease opacities in the descemet’s membrane, sunflower cataract and pigmented corneal rings 
called as Kayser-Fleischer (K-F) rings
Mucopolysacharidosis corneal clouding, thickening of the sclera at the lamina cribrosa, optic nerve head 
deformation and impingement of the nerve, and often optic nerve atrophy
Partial Lecithin carnitine acyl 
transferase (LCAT) deficiency
Fish-eye disease, impaired vision due to corneal opacification
Galactosaemia Galactitol leads to toxic opacification and lens swelling; shift of water into the lens and 
disruption of lens structure
Cerebrotendinous xanthomatosis bilateral cataracts, optic disc pallor, proptosis and fleck lenticular deposits
Zellweger syndrome corneal opacification, cataract, glaucoma, pigmentary retinopathy and optic atrophy
Marfan’s syndrome ectopia lentis, iridodonesis, retinal detachment and glaucoma
Homocystinuria ectopia lentis
Sulphite oxidase deficiency and 
molybdenum cofactor deficiency
opacities of the crystalline lens and ectopia lentis
Ehler-Danlos syndrome keratoconus, fragility of the eye, dry eyes and tunnel vision
Retinitis pigmentosa pigment deposits in the fundus and progressive death of photoreceptors, alteration of retinal 
pigment epithelium and retinal degeneration
Ornithine aminotransferase deficiency gyrate atrophy of the choroid and retina, myopia which progresses to night blindness
Batten’s disease (Juvenile Neuronal 
Ceroid Lipofuscinosis)
hallmarks of the disease include rapid vision loss due to retinal degeneration
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Lab & Rad Mesh up for the Early Recognition 
of Rare Disorders
Dr Sibtain Ahmed 
Clinical Chemistry
Disorder Radiological Findings Biochemical Findings
Urea cycle 
disorders
•	 Conventional Magnetic Resonance Imaging (MRI): diffuse generalized 
cytotoxic edema, abnormal signal of Basal Ganglia (T1-/T2-hyper of the 
globi pallidi, T2-hyper of putamina and caudate nuclei)
•	 Magnetic resonance spectroscopy: prominent glutamine/ glutamate 
peaks
•	 Diffusion Weighted Imaging- MRI: scalloped ribbon of restriction at 
the depth of sulci
↑ ammonia, glutamine and 
citrulline levels on plasma amino 
acid analysis
↑ Orotic acid on urine organic 
acid analysis in few of the UCDs 
↑ Plasma Ammonia
Often Respiratory alkalosis 
Maple syrup 
urine disease
•	 Conventional MRI:  increased signal of myelinated structures 
(cerebellar and perirolandic, dorsal brainstem, cerebral peduncles, 
Posterior limb of internal capsule, thalami and globi pallidi)
•	 Magnetic resonance spectroscopy: branched-chain amino and ketoacids 
(0.9 ppm)
•	 Diffusion Weighted Imaging- MRI: Diffusion restriction of myelinated 
structures (cerebellar and perirolandic white matter, dorsal brainstem, 
cerebral peduncles, Posterior limb of internal capsule, thalami and globi 
pallidi), superimposed vasogenic edema of unmyelinated White Matter
↑ Branched chain aminoacids in 
plasma
↑ Alpha ketoacids in urine
↑ Alloisoleucine in plasma is 
diagnostic
↑ Ketones in urine
Metabolic Acidosis
Glutaric aciduria 
type 1
•	 Conventional MRI: enlarged fronto-temporal CSF spaces, wide Sylvian 
fissures
↑ Glutaric acid, 3-OH gluaric 
acid and glutaconic acid in urine 
↓ glutaryl-CoA dehydrogenase 
enzyme activity in cultured 
fibroblasts or leukocytes
Nonketotic 
hyperglycinemia
•	 Conventional MRI: T2-hyper lesions of the myelinated white matter 
tracts, Corpus callsoum agenesis, vermian hypoplasia
•	 Magnetic resonance spectroscopy: glycine peak
↑ glycine in plasma and CSF
Methylmalonic 
Acidemia
•	 Conventional MRI: Diffuse swelling, volume loss, delay in myelin 
maturation, calcification of the basal ganglia, and focal necrosis of the 
globi pallidi
↑ ammonia
↑Glycine on plasma Amino acid
↑ Ethylmalonic acid, 
methylcitrate, propionic acid, 
3-hydroxy isovaleric acid, 
propionylglycine, tiglylglycine 
and 3-hydroxy propionate on 
urine organic acid
L-2-
Hydroxyglutaric 
(L-2-HG) aciduria
•	 Conventional MRI: nonspecific subcortical white matter loss, cerebellar 
atrophy, changes in dentate nuclei and putamen
↑ L-2-HG in body fluids
Hyperphenylalan
inemia
•	 MRI T2/FLAIR: high signal in affected areas occurring firstly in 
the periventricular/parieto-occipital white matter before eventually 
affecting the subcortical white matter, atrophy and compensatory 
ventricular dilatation may occur eventually
•	 Diffusion Weighted Imaging- MRI: reduced diffusion in acutely 
affected areas 
•	 Magnetic resonance spectroscopy: phenylalanine peak 
↑ Phenylalanine levels on plasma 
amino acid analysis 
↑ Phenylalanine to Tyrosine ratio 
in Plasma
X-linked 
noleukodystrophy
•	 Conventional MRI: Symmetric peritrigonal abnormality with 
involvement of the splenium of the corpus callsoum, abnormal 
peripheral enhancement
↑ very long chain fatty acids 
by gas chromatography/ mass- 
spectrometry
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News from Chemical Pathology: Section of Chemical Pathology conducted a three, half days course on 
‘Fundamentals of Quality Control to improve patient safety’ on 4-6th December 2019. 
Shown above is group picture of participants, facilitators and organizers of the course.
Dr. Natasha Ali presented poster on “Outcome of aplastic anemia using GCSF primed blood and bone marrow stem 
cells” at Transplantation & Cellular Therapy meeting held in Florida (February 2020)
Polaroid
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Group of doctors and technical staff from Middle East region has been trained to perform Line probe assay (LiPA) 
for the diagnosis of tuberculosis by microbiology section
Dr Saira Fatima and Muhammad Usman Tariq from section of Histopathology presented their posters at 
“The 59th IAP Thailand Annual Meeting”
Polaroid
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Haematology Faculty of AKU attended 22nd Annual meeting of Pakistan Society of Haematology, 
held in Lahore (February 2020)
Inauguration of the remodeled lab (histopathology section) by the President Mr. Feroz Rasul
Polaroid
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Learning through Assessment: 1st FCPS part II Histopathology Mock Examination, Conducted 
on November 6-7, 2019.
Polaroid
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Dr Sheema receiving token of appreciation by the Dean, Adil Haider, Interim CEO Shagufta Hassan and 
Departmental Chair Dr Afia Zafar
Party in the honor of Professor Sheema Hasan - retired on 21st of November 2019
Polaroid
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THE AGA KHAN UNIVERSITY HOSPITAL CLINICAL LABORATORIES
UPDATE
Detection of Novel Coronavirus SARS-CoV for COVID 19 - by 
Real Time PCR
Introduction 
Coronaviruses, named for the crown-like spikes on their surface. The SARS-CoV-2 has now been identified 
as the causative agent of COVID 19 disease. Around the world, most common mild to moderate respiratory 
coronavirus infections in humans are by 229E, NL63, OC43, and HKU1. wo zoonotic coronaviruses, SARSCoV 
(2002-2003) and MERS-CoV (since 2015), are known to cause severe illness in humans. A recent example of 
such emergence from Wuhan, China is the novel coronavirus, SARS-CoV-2. Person-to-person spread of SARS-
CoV-2 is via respiratory droplets produced when an infected person coughs or sneezes. The incubation period is 
2-14 days. Symptoms include fever, cough and shortness of breath; suspicion increases when patient has history 
of travel to affected areas (especially China, Iran, Iraq and other countries which have reported COVID 19) in 
the last 2 weeks. All such patients who need hospitalization for management, should be tested at the earliest and 
contact isolation precautions instituted till SARS-CoV-2 infection has been ruled out. 
Reliable diagnosis of virus can only be done using a targeted PCR based test.  Serology or blood based antibody 
testing is an indirect measure of infection/exposure and cannot be used for confirmatory diagnosis of SARS-
CoV-2.
Principle of the Assay: 
Real-time (RT- PCR) assays for the in vitro qualitative detection of Novel Coronavirus-2019 (nCoV-2019) is used. 
Results interpretation is based on detection of fluorescent signals. 
Specimen Collection: 
• Upper respiratory specimens including nasopharyngeal or oropharyngeal swabs in a special tube containing 
Universal Transport Medium (available from the clinical laboratory) 
• Lower respiratory specimens including Broncho-alveolar Lavage (BAL), tracheal aspirates and sputum in sterile 
container. 
Reporting Schedule: 
SARS-CoV-2 virus RT-PCR is performed and reported daily if specimen is received before cut off 11:00 am
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